{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:40:53Z","timestamp":1791171653196,"version":"4.1.0"},"reference-count":36,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2013,1,3]],"date-time":"2013-01-03T00:00:00Z","timestamp":1357171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The characterization of the viral life cycle facilitated the development of directly acting antiviral drugs. Among those, several inhibitors of the viral RNA\u2010dependent RNA polymerase have proven effectiveness in clinical trials. The characteristics of different nucleos(t)ide and non\u2010nucleoside polymerase inhibitors, as well as their clinical applications and combinations with other classes of directly acting antiviral drugs are reviewed herein.<\/jats:p>","DOI":"10.1111\/liv.12068","type":"journal-article","created":{"date-parts":[[2013,1,3]],"date-time":"2013-01-03T11:25:14Z","timestamp":1357212314000},"page":"85-92","source":"Crossref","is-referenced-by-count":45,"title":["New therapeutic strategies in HCV: polymerase inhibitors"],"prefix":"10.1111","volume":"33","author":[{"given":"Ludmila","family":"Gerber","sequence":"first","affiliation":[{"name":"Klinikum der J.W. Goethe Universit\u00e4t Frankfurt am Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania M.","family":"Welzel","sequence":"additional","affiliation":[{"name":"Klinikum der J.W. Goethe Universit\u00e4t Frankfurt am Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[{"name":"Klinikum der J.W. Goethe Universit\u00e4t Frankfurt am Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,3]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"WHO. Hepatitis C: Available athttp:\/\/www.who.int\/csr\/disease\/hepatitis\/whocdscsrlyo2003\/en\/index3.html. Accessed: August 2012."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.01012.x"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2523562"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81351-3"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.23.13034"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1645"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/13305"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M413410200"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.11.055"},{"key":"e_1_2_10_13_1","first-page":"1219A","article-title":"Phase I study in healthy volunteers and patients with IDX\u2010375, a novel non\u2010nucleoside HCV polymerase inhibitor","volume":"52","author":"de Bruijne J","year":"2010","journal-title":"Hepatology"},{"key":"e_1_2_10_14_1","first-page":"360","article-title":"High rates of early viral response, promising safety profile and lack resistance\u2010related breakthrough in HCV GT1\/4 patients treated with RG7128 plus pegIFN alfa\u20102a (40KD)\/RBV: planned week 12 interim analysis from the PROPEL study","volume":"52","author":"Jensen DM","year":"2010","journal-title":"Hepatology"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61217-3"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)60021-X"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(11)60063-9"},{"key":"e_1_2_10_18_1","first-page":"306","article-title":"Once daily GS\u20107977 plus ribavirin in HCV genotypes 1\u20103: the ELECTRON","volume":"56","author":"Gane EJ","year":"2012","journal-title":"Hepatology"},{"key":"e_1_2_10_19_1","first-page":"307A","article-title":"Once daily sofosbuvir (GS\u20107977) plus PEG\/RBV: high early response rates are maintained during post\u2010treatment follow\u2010up in treatment\u2010na\u00efve patients with HCV genotype 1, 4, and 6 infection in the ATOMIC study","volume":"56","author":"Hassanein T","year":"2012","journal-title":"Hepatology"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61384-0"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61423-8"},{"key":"e_1_2_10_22_1","unstructured":"Gilead Announces Early Sustained Virologic Response Rates for GS\u20107977 Plus Ribavirin in Genotype 1 Treatment\u2010Naive Hepatitis C Patients: Available athttp:\/\/investors.gilead.com\/phoenix.zhtml?c&#x00A0;=&#x00A0;69964&p=irol-newsArticle&ID=1684792&highlight. Accessed: October 2012."},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61433-0"},{"key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/135965350901400104","article-title":"Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5\u00a0days oral treatment","volume":"14","author":"Erhardt A","year":"2009","journal-title":"Antivir Ther"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(09)61056-4"},{"key":"e_1_2_10_26_1","first-page":"1026\u20107A","article-title":"Safety and antiviral activity of NS5B polymerase inhibitor MK\u20103281, in treatment\u2010naive genotype 1a, 1b and 3 HCV\u2010infected patients","volume":"50","author":"Brainard DM","year":"2009","journal-title":"Hepatology"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.03.015"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(09)60094-5"},{"key":"e_1_2_10_29_1","first-page":"486\u20107A","article-title":"High SVR following IFN\u2010free treatment of chronic HCV GT1 infection for 4\u00a0weeks with HCV protease inhibitor BI 201335, polymerase inhibitor BI 207127 and ribavirin, followed by BI 201335 and PegIFN\/ribavirin \u2013 the SOUND\u2010C1 study","volume":"54","author":"Zeuzem S","year":"2011","journal-title":"Hepatology"},{"key":"e_1_2_10_30_1","first-page":"1435A","article-title":"VX\u2010222\/telaprevir in combination with peginterferon\u2010alfa\u20102a and ribavirin in treatment\u2010naive genotype 1 HCV patients treated for 12\u00a0weeks: ZENITH study, SVR12 interim analysis","volume":"54","author":"Nelson DR","year":"2011","journal-title":"Hepatology"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(09)61057-6"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24744"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)60026-9"},{"key":"e_1_2_10_34_1","unstructured":"Vertex Announces Positive Results from Viral Kinetic Study of the Nucleotide Analogue ALS\u20102200 in People with Hepatitis C: Available athttp:\/\/investors.vrtx.com\/releasedetail.cfm?releaseid=696581. Accessed: October 2012."},{"key":"e_1_2_10_35_1","first-page":"1436A","article-title":"Virologic response to an interferon\u2010free regimen of BI 201335 and BI 207127, with and without ribavirin, in treatment\u2010naive patients with chronic genotype\u20101 HCV infection: week 12 interim results of the SOUND\u2010C2 study","volume":"54","author":"Zeuzem S","year":"2011","journal-title":"Hepatology"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61410-X"},{"key":"e_1_2_10_37_1","first-page":"298A","article-title":"Complete SVR4 rates in treatment\u2010na\u00efve HCV genotype 1a and 1b patients who achieved vRVR with an interferon\u2010free all\u2010oral regimen","volume":"56","author":"Sulkowski M","year":"2012","journal-title":"Hepatology"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12068","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12068","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.12068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T16:16:31Z","timestamp":1694621791000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.12068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,3]]},"references-count":36,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1111\/liv.12068"],"URL":"https:\/\/doi.org\/10.1111\/liv.12068","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,3]]}}}